These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 18319360)

  • 1. Disposition and antimuscarinic effects of the urinary bladder spasmolytics propiverine: influence of dosage forms and circadian-time rhythms.
    May K; Westphal K; Giessmann T; Wegner D; Adam U; Lerch MM; Oertel R; Warzok RW; Weitschies W; Braeter M; Siegmund W
    J Clin Pharmacol; 2008 May; 48(5):570-9. PubMed ID: 18319360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral absorption of propiverine solution and of the immediate and extended release dosage forms: influence of regioselective intestinal elimination.
    May K; Giessmann T; Wegner D; Oertel R; Modess C; Oswald S; Braeter M; Siegmund W
    Eur J Clin Pharmacol; 2008 Nov; 64(11):1085-92. PubMed ID: 18626633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling the heterogeneous intestinal absorption of propiverine extended-release.
    Weiss M; Sermsappasuk P; Siegmund W
    Eur J Pharm Sci; 2015 Aug; 76():133-7. PubMed ID: 25976222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of a fat-rich meal on bioavailability of extended-release and immediate-release propiverine.
    Siegmund W; Siegert J; Richter K; Schnabel F; Feustel C; Kirch W
    J Clin Pharmacol; 2012 May; 52(5):681-90. PubMed ID: 21551317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of propiverine in children aged between 5 and 10 years with symptoms of overactive bladder.
    Siegmund W; Sillén U; Läckgren G; Schnabel F; Mürtz G; Feustel C
    Clin Pharmacokinet; 2010 May; 49(5):335-42. PubMed ID: 20384395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The N-oxide metabolite contributes to bladder selectivity resulting from oral propiverine: muscarinic receptor binding and pharmacokinetics.
    Yamada S; Ito Y; Taki Y; Seki M; Nanri M; Yamashita F; Morishita K; Komoto I; Yoshida K
    Drug Metab Dispos; 2010 Aug; 38(8):1314-21. PubMed ID: 20483954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir.
    van Waterschoot RA; ter Heine R; Wagenaar E; van der Kruijssen CM; Rooswinkel RW; Huitema AD; Beijnen JH; Schinkel AH
    Br J Pharmacol; 2010 Jul; 160(5):1224-33. PubMed ID: 20590614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder.
    Homma Y; Yamaguchi O;
    Int J Urol; 2009 May; 16(5):499-506. PubMed ID: 19389083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder.
    Jünemann KP; Hessdörfer E; Unamba-Oparah I; Berse M; Brünjes R; Madersbacher H; Gramatté T
    Urol Int; 2006; 77(4):334-9. PubMed ID: 17135784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a randomized, double-blind, active-controlled clinical trial with propiverine extended release 30 mg in patients with overactive bladder.
    Leng J; Liao L; Wan B; Du C; Li W; Xie K; Shen Z; Xu Z; Wu S; Fang Z; Ma L; Han S; Feustel C; Yang Y; Madersbacher H
    BJU Int; 2017 Jan; 119(1):148-157. PubMed ID: 27087507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimuscarinic drug inhibits detrusor overactivity induced by topical application of prostaglandin E2 to the urethra with a decrease in urethral pressure.
    Yokoyama O; Miwa Y; Oyama N; Aoki Y; Ito H; Akino H
    J Urol; 2007 Nov; 178(5):2208-12. PubMed ID: 17870108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome.
    Abrams P; Cardozo L; Chapple C; Serdarevic D; Hargreaves K; Khullar V;
    Int J Urol; 2006 Jun; 13(6):692-8. PubMed ID: 16834644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: A randomized double-blind trial.
    Yamaguchi O; Uchida E; Higo N; Minami H; Kobayashi S; Sato H;
    Int J Urol; 2014 Jun; 21(6):586-93. PubMed ID: 24350662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics of drugs used to treat urge incontinence.
    Guay DR
    Clin Pharmacokinet; 2003; 42(14):1243-85. PubMed ID: 14606931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics of trospium chloride.
    Doroshyenko O; Jetter A; Odenthal KP; Fuhr U
    Clin Pharmacokinet; 2005; 44(7):701-20. PubMed ID: 15966754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the P-Glycoprotein Inhibitor Clarithromycin on the Pharmacokinetics of Intravenous and Oral Trospium Chloride: A 4-Way Crossover Drug-Drug Interaction Study in Healthy Subjects.
    Abebe BT; Weiss M; Modess C; Roustom T; Tadken T; Wegner D; Schwantes U; Neumeister C; Schulz HU; Scheuch E; Siegmund W
    J Clin Pharmacol; 2019 Oct; 59(10):1319-1330. PubMed ID: 30973998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of once-daily controlled-release oxybutynin and immediate-release oxybutynin.
    Reiz JL; Salem P; Darke AC
    J Clin Pharmacol; 2007 Mar; 47(3):351-7. PubMed ID: 17322147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
    Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
    Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin.
    Gupta SK; Sathyan G
    J Clin Pharmacol; 1999 Mar; 39(3):289-96. PubMed ID: 10073329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Long-term administration study of propiverine hydrochloride (BUP-4 tablets) in pollakiuria and urinary incontinence].
    Noguchi K; Masuda M; Noguchi S; Kubota Y; Hosaka M; Senga Y; Sano K; Miyai K; Kanno H; Kitami K; Fujinami K; Miura T; Kondo I; Kawasaki C; Moriyama M; Hara Y; Ida T; Fukuoka H; Nakagawa J; Kitajima N; Fukuda M; Satomi Y; Takahashi T; Yamaguchi T; Shiozaki H
    Hinyokika Kiyo; 1998 Sep; 44(9):687-93. PubMed ID: 9805679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.